Aug 5, 2024 · In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, as an adjunctive treatment for patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.

Feb 21, 2023 · Renal denervation may be of use in adults with uncontrolled or resistant hypertension (triple drug therapy, one of which is a diuretic) and may be an option for patients unable to tolerate long-term medications at the necessary doses or who cannot tolerate medications at all.

Jan 2, 2025 · Renal denervation (RDN) is a catheter-based therapy for hypertension that reduces sympathetic nervous system activity; RDN is usually an outpatient procedure performed in a...

Ten percent of patients (5 of 50 patients enrolled) in the Renal Denervation in Patients With Refractory Hypertension (Symplicity HTN)‐1 trial and 16% (30 of 190 screened) in Symplicity HTN‐2 were excluded for anatomic reasons.8, 9 Currently, no RSD devices are approved by the Food and Drug Administration. To date, several devices have been ...

Aug 14, 2024 · Transcatheter renal denervation (RDN) is an innovative treatment for hypertension that acts via a completely new mechanism of action (ie, denervation of renal sympathetic nerves distributed around the renal artery from the lumen of the vessel). 1 In the time since the first clinical trial of RDN showed that the procedure markedly reduced blood p...

Apr 16, 2025 · SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) was a randomized, sham-controlled trial that enrolled 535 patients with uncontrolled resistant hypertension despite taking three or more anti-hypertensive drugs at the maximum tolerated dose. The aim was to evaluate the efficacy of RDN in reducing SBP.

In this issue of JSCAI, the Society for Cardiovascular Angiography & Interventions (SCAI) publishes an updated expert consensus statement on renal denervation for hypertension, reviewing appropriate patient selection, optimal procedural and technical considerations, as well as center qualification. 8 The expert group acknowledged that renal dene...

Aug 5, 2024 · In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, as an adjunctive treatment for patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.

2 days ago · 80 of the 467 patients met the inclusion criteria. They underwent renal angiography to rule out secondary hypertension and were randomized equally into two groups, with one group being treated with renal denervation (n = 38) and the control group with a sham procedure (n = 42). The primary endpoint was the difference in mean 24-h systolic blood ...

Apr 5, 2021 · One potential treatment is renal denervation (RDN), a minimally invasive catheter-based technology that uses radiofrequency energy to obliterate the renal nerves adjacent to the afferent and efferent renal arteries.